| Sontak Family Clinic Pllc | |
|
4023 State St Ste 60 Bismarck ND 58503-0690 | |
| (701) 390-2431 | |
| Not Available |
| Full Name | Sontak Family Clinic Pllc |
|---|---|
| Speciality | Clinic/Center |
| Location | 4023 State St Ste 60, Bismarck, North Dakota |
| Authorized Official Name and Position | Sonia Takacs (PROVIDER) |
| Authorized Official Contact | 7017511281 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sontak Family Clinic Pllc 4023 State St Ste 60 Bismarck ND 58503-0690 Ph: () - | Sontak Family Clinic Pllc 4023 State St Ste 60 Bismarck ND 58503-0690 Ph: (701) 390-2431 |
| NPI Number | 1174138507 |
|---|---|
| Provider Enumeration Date | 09/11/2020 |
| Last Update Date | 11/04/2020 |
| Medicare PECOS PAC ID | 8123430691 |
|---|---|
| Medicare Enrollment ID | O20201208001097 |
News Archive
All of us who have been at this task before understand three important realities: One, no president who has launched such an effort unsuccessfully has ever been able to relaunch; two, the Senate legislation, at least, has been the product of much bipartisan effort over the last several years, even though no Republican senators voted for it, and three, the status quo costs and quality of this country's health care system are totally unacceptable - to the health care industry and to those who depend on it (Dave Durenberger, 2/18).
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Revolutions Medical Corporation announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174138507 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Sonia D Takacs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447804679 PECOS PAC ID: 9931430089 Enrollment ID: I20191003003715 |
News Archive
All of us who have been at this task before understand three important realities: One, no president who has launched such an effort unsuccessfully has ever been able to relaunch; two, the Senate legislation, at least, has been the product of much bipartisan effort over the last several years, even though no Republican senators voted for it, and three, the status quo costs and quality of this country's health care system are totally unacceptable - to the health care industry and to those who depend on it (Dave Durenberger, 2/18).
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Revolutions Medical Corporation announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes.
› Verified 2 days ago
News Archive
All of us who have been at this task before understand three important realities: One, no president who has launched such an effort unsuccessfully has ever been able to relaunch; two, the Senate legislation, at least, has been the product of much bipartisan effort over the last several years, even though no Republican senators voted for it, and three, the status quo costs and quality of this country's health care system are totally unacceptable - to the health care industry and to those who depend on it (Dave Durenberger, 2/18).
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Revolutions Medical Corporation announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes.
› Verified 2 days ago
Lung Disease And Infection Consultants Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 210 S 12th St, Bismarck, ND 58504 Phone: 701-223-4234 Fax: 701-222-0712 | |
Prairie Assisted Living Services Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4914 Amberglow Dr, Bismarck, ND 58503 Phone: 701-226-9804 Fax: 701-751-1307 | |
Inspired Life Wellness Clinic, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3100 Moonstone Ln, Bismarck, ND 58503 Phone: 701-989-4354 Fax: 701-213-4335 | |
Essentia Health Mid Dakota Bismarck 9th St Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 401 N 9th St, Bismarck, ND 58501 Phone: 701-712-4500 | |
Wellness Rediscovered P.l.l.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 705 E Main Ave, Bismarck, ND 58501 Phone: 701-269-9455 | |
Tru Health & Wellness Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 705 E Main Ave, Bismarck, ND 58501 Phone: 701-226-4432 | |
Lifeways Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1001 Gateway Avenue, Bismarck, ND 58503 Phone: 701-751-3271 |